CLINICAL TRIALS PROFILE FOR AMYVID
✉ Email this page to a colleague
All Clinical Trials for AMYVID
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00702143 ↗ | A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) | Completed | Avid Radiopharmaceuticals | Phase 2 | 2008-06-01 | Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI). |
| NCT00857415 ↗ | Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain | Completed | Avid Radiopharmaceuticals | Phase 3 | 2008-12-01 | The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD). |
| NCT00857532 ↗ | Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 2009-01-01 | The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls. |
| NCT00857532 ↗ | Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients | Completed | National Institutes of Health (NIH) | Phase 2 | 2009-01-01 | The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls. |
| NCT00857532 ↗ | Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients | Completed | Avid Radiopharmaceuticals | Phase 2 | 2009-01-01 | The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls. |
| NCT01400425 ↗ | Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline | Completed | Avid Radiopharmaceuticals | Phase 3 | 2011-07-01 | The study is designed to evaluate whether a florbetapir F 18 PET scan can impact clinical thinking when physicians are determining the likely cause of a subject's cognitive impairment. |
| NCT01518374 ↗ | Clinical Evaluation of Florbetapir F 18 (18F-AV-45) | Completed | Avid Radiopharmaceuticals | Phase 2 | 2009-12-01 | This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging and studies of biomarkers for neurodegenerative diseases. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMYVID
Condition Name
Clinical Trial Locations for AMYVID
Trials by Country
Clinical Trial Progress for AMYVID
Clinical Trial Phase
Clinical Trial Sponsors for AMYVID
Sponsor Name
